nad has been researched along with niraparib in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Estes, VM; Langelier, MF; Lee, BJ; Lin, X; Pascal, JM; Rouleau-Turcotte, É; Shao, Z; Zha, S | 1 |
1 other study(ies) available for nad and niraparib
Article | Year |
---|---|
Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo.
Topics: Binding Sites; Catalytic Domain; Cell Line, Tumor; DNA Damage; DNA Repair; Fluorescence Resonance Energy Transfer; Green Fluorescent Proteins; Humans; Indazoles; Kinetics; Molecular Imaging; NAD; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Recombinant Proteins; X-ray Repair Cross Complementing Protein 1 | 2020 |